On April 3, 2014, BG Medicine, Inc. (NASDAQ:BGMD), entered into an underwriting agreement (the “Underwriting Agreement”) with Lazard Capital Markets LLC (the “Underwriter”) pursuant to which the Company agreed to sell to the Underwriter in a firm commitment underwritten public offering an aggregate of 6,452,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”, and the offering of the Shares, the “Offering”), at a price to the public of $1.55 per share, less underwriting discounts and commissions. BG Medicine, Inc. (NASDAQ:BGMD) shares after opening at $1.22 moved to $1.50 on last trade day and at the end of the day closed at $1.27. Company price to sales ratio in past twelve months was calculated as 10.66 and price to cash ratio as 5.60. BG Medicine, Inc. (NASDAQ:BGMD) showed a negative weekly performance of -4.51%.
Exact Sciences Corp. (NASDAQ:EXAS) reported wider losses for the quarter that ended March 31. Exact Sciences had $116 million in cash and equivalents available as of March 31, and closed on a secondary public stock offering on April 9 with net proceeds of $137.7 million. EXACT Sciences Corporation (NASDAQ:EXAS) shares advanced 4.63% in last trading session and ended the day on $12.56. EXAS return on equity ratio is recorded as -35.60% and its return on assets is -33.00%. EXACT Sciences Corporation (NASDAQ:EXAS) yearly performance is 38.73%.
Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, hosted a conference call on 30 April to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol), which the Company is developing as a once-daily adjunctive oral treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Synthetic Biologics Inc. (NYSEMKT:SYN) shares moved down -1.03% in last trading session and was closed at $1.43, while trading in range of $1.40 – $1.65. Synthetic Biologics Inc. (NYSEMKT:SYN) year to date (YTD) performance is -6.21%.
Research analysts at Laidlaw began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Tuesday, American Banking News.com reports. The firm set a “buy” rating and a $19.00 price target on the stock. Laidlaw’s price objective indicates a potential upside of 94.27% from the stock’s previous close. Evoke Pharma Inc. (NASDAQ:EVOK) weekly performance is -13.07%. On last trading day company shares ended up $8.78. Evoke Pharma Inc. (NASDAQ:EVOK) distance from 50-day simple moving average (SMA50) is -5.31%. Analysts mean target price for the company is $26.40.